Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Return on Sales (2016 - 2024)

Seres Therapeutics' Return on Sales history spans 10 years, with the latest figure at 226.23% for Q2 2025.

  • For Q2 2025, Return on Sales rose 61503.0% year-over-year to 226.23%; the TTM value through Jun 2025 reached 226.23%, up 61503.0%, while the annual FY2023 figure was 0.6%, 994.0% up from the prior year.
  • Return on Sales for Q2 2025 was 226.23% at Seres Therapeutics, up from 215.43% in the prior quarter.
  • Across five years, Return on Sales topped out at 226.23% in Q2 2025 and bottomed at 1947.95% in Q4 2023.
  • The 5-year median for Return on Sales is 6.51% (2021), against an average of 109.07%.
  • The largest annual shift saw Return on Sales crashed -194570bps in 2023 before it skyrocketed 215169bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 6.88% in 2021, then surged by 67bps to 2.25% in 2022, then tumbled by -86348bps to 1947.95% in 2023, then skyrocketed by 110bps to 203.73% in 2024, then increased by 11bps to 226.23% in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Return on Sales are 226.23% (Q2 2025), 215.43% (Q1 2025), and 203.73% (Q4 2024).